Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)

Summary

This study represents the largest to date evaluating the impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving front-line osimertinib. Researchers analyzed data from patients within a U.S. clinical-genomic database. The findings indicated that the presence of either the EGFR L858R mutation or a TP53 co-mutation independently predicted inferior real-world progression-free survival (rwPFS) and overall survival (OS). Patients with both unfavorable alterations (EGFR L858R and mutant TP53) experienced the shortest survival, with a median rwPFS of 10.1 months and a median OS of 21.3 months. This risk stratification could assist in identifying patients who might benefit from novel trials or intensified therapies.

Critical appraisal

This retrospective, real-world study, involving a large cohort of 606 patients, identifies significant prognostic and potentially predictive biomarkers for EGFR-mutant NSCLC patients treated with front-line osimertinib. The presence of either the EGFR L858R mutation (rwPFS HR 1.4, OS HR 1.3) or a TP53 co-mutation (rwPFS HR 1.5, OS HR 1.6) is associated with significantly inferior clinical outcomes. The impact is particularly pronounced when both alterations are present, leading to a median rwPFS of 10.1 months and a median OS of 21.3 months, compared to 21.4 and 53.4 months respectively for patients without these markers. These markers are prognostic and potentially predictive of osimertinib response. These findings justify the design of phase II/III clinical trials evaluating intensified therapeutic strategies or combination treatments for patients harboring these unfavorable alterations, especially those with EGFR L858R and mutant TP53. This could potentially change clinical practice within 3 to 5 years by enabling more precise risk stratification and early adaptation of treatments.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology